gleevec imatinib mesylate page 1 gleevec imatinib mesylate advancing the treatment of ph+ chronic myeloid leukemia cml page 2 cml a progressive and fatal disease page 3 cml linked to a single molecular abnormality page 4 cml its cause and management page 5 gleevec targets the cause of cml page 6 gleevec pharmacokinetics page 7 phase i study gleevec achieves hematologic and cytogenetic responses page 8 phase ii results highest response rates in chronic phase page 9 higher dose longer time to disease progression page 10 iris study reevaluating first line cml therapy page 11 iris the largest phase iii cml study to date page 12 longer time to progression with gleevec page 13 higher cytogenetic response rates with gleevec page 14 early responses in more patients with gleevec page 15 more patients remain on gleevec therapy page 16 most non hematologic adverse events less common with gleevec page 17 fewer hematologic adverse events with gleevec page 18 gleevec cml indications page 19 gleevec important considerations page 20 gleevec evolving first line cml therapy page 21 inhibition of cellular proliferation by gleevec http www biocarta com pathfiles h_gleevecpathway asp page 22 cdk regulation of cell division http www biocarta com genes page 23 il7 regulatory pathway http www biocarta com pathfiles h_il7pathway asp page 24 growth hormone receptor pathway http www biocarta com pathfiles h_ghpathway asp page 25 nccn cml guidelines for monitoring response to gleevec page 26 optimal dosing for optimal results page 27 gleevec has advanced the treatment of ph+ cml
